Clinical trials: Patients With Tumor
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma
Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This study will evaluate the safety and effectiveness of a new drug called lenalidomide (Revlimid) for treating patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who relapsed after their…
- Trial name
- NCT00439231
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Georg Aue, M.D.
Ovarian Cancer
Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006453
- Testing
- carboplatin, gemcitabine hydrochloride
- Where
- 74 sites in United States, Canada
- Sponsor
- AGO Study Group
Tumors
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
Primary Objective Dose Escalation: To evaluate the safety and tolerability of surufatinib in patients with advanced solid tumors and to determine the maximum tolerable dose (MTD) or recommended phase II dose (RP2D).
- Trial name
- NCT02549937
- Testing
- surufatinib
- Where
- 12 sites in United States, Italy
- Volunteers
- 130 people
- Sponsor
- Hutchmed
Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression
Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients
To evaluate the efficacy and safety of glumetinib combined with osimertinib as the first-line treatment for locally advanced or metastatic NSCLC.
- Trial name
- NCT06908772
- Testing
- Glumetinib Tablets, Osimertinib Mesylate Tablets
- Volunteers
- 390 people
- Sponsor
- Shanghai JMT-Bio Inc.
Lymphoma
Cyclophosphamide and Filgrastim in Treating Patients With Stage IV, Relapsed, or Refractory Low-Grade Follicular Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of cyclophosphamide and filgrastim in treating patients…
- Trial name
- NCT00002501
- Testing
- filgrastim, cyclophosphamide
- Where
- 15 sites in United States
- Volunteers
- 29 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lung Cancer
Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo
This study is intended for participants with advanced, not amenable to surgery, or metastatic lung cancer who have not received any prior chemotherapy.
- Trial name
- NCT00538681
- Testing
- enzastaurin, pemetrexed, cisplatin
- Where
- 12 sites in Belgium, Germany and 3 more
- Volunteers
- 35 people
- Sponsor
- Eli Lilly and Company
Thyroid Neoplasms, Carcinoma
Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer
Anaplastic Thyroid Cancer is a very aggressive disease. The investigators believe that angiogenesis is very important for these tumors to progress. Preclinical data is suggesting this.
- Conditions
- Thyroid Neoplasms, Carcinoma, Thyroid Cancer, Metastatic Cancer
- Trial name
- NCT00804830
- Testing
- Bevacizumab
- Where
- 3 sites in Sweden
- Volunteers
- 15 people
- Sponsor
- Region Skane
Advanced Solid Cancers, Breast Cancer
A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors
This is a phase 1 study of investigational agent CFI-402257 in patients with advanced cancer. The purpose of this study is to see how safe and tolerable CFI-402257 is in cancer patients as well as the pharmacokinetics (PK).
- Trial name
- NCT02792465
- Testing
- CFI-402257, Fulvestrant
- Where
- 3 sites in Canada
- Volunteers
- 52 people
- Sponsor
- University Health Network, Toronto
Adenocarcinoma of the Lung, Large Cell Lung Cancer
Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC
This phase I trial studies the side effects and best dose of image-guided adaptive radiation therapy using active breathing control when given together with chemotherapy and simultaneous integrated boost in treating patients with…
- Conditions
- Adenocarcinoma of the Lung, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer
- Trial name
- NCT02059967
- Testing
- Paclitaxel, image-guided adaptive radiation therapy, carboplatin
- Sponsor
- Virginia Commonwealth University
HER2-positive Breast Cancer
Omission of Radiation in Patients With Her-2 Positive Breast Cancer
The primary objective of this study is to describe the rate of local control in patients with her-2 positive early stage breast cancer with a complete response to chemotherapy and lumpectomy alone.
- Trial name
- NCT03460067
- Testing
- Omission of Radiation
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Kansas Medical Center
Intrahepatic Cholangiocarcinoma
Cryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic Cholangiocarcinoma
This study will evaluate the efficacy and safety of cryoablation combined with Anlotinib plus TQB2868 in patients with advanced Intrahepatic Cholangiocarcinoma (ICC) who have progressed after first-line treatment.
- Trial name
- CASTLE-ZS-05 (NCT07846267)
- Testing
- Anlotinib, TQB2868 Injection, cryoablation
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Fudan University
Solid Tumors
rhEndostatin Protein Involving Pediatric Patients With Cancer
The purpose of this study is to assess the safety of rhEndostatin, to determine how much of the drug stays in the patients blood (pharmacokinetics), to assess the development of proteins in the blood that are produced by the body…
- Trial name
- NCT00165373
- Testing
- rhEndostatin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Dana-Farber Cancer Institute
Neoplasms
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
This open-label, dose-finding, and proof of concept study will evaluate the safety, tolerability, maximum-tolerated dose (MTD) and/or optimal dose of nenocorilant when administered in combination with nivolumab in patients with…
- Trial name
- NCT07276373
- Testing
- Nenocorilant 200 mg, Nenocorilant 300 mg, Nenocorilant 400 mg
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Corcept Therapeutics
Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery
This phase II trial studies how well cemiplimab works before surgery in treating patients with stage II-IV head and neck cutaneous squamous cell cancer that has come back (recurrent) and can be removed by surgery (resectable).
- Conditions
- Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
- Trial name
- NCT03565783
- Testing
- Cemiplimab
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- M.D. Anderson Cancer Center
Resistant or Refractory Solid Tumors
Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors
This is a multi-center, open-label, dose-escalation, phase I study to evaluate the safety, tolerability, pharmacokinetics (PK), preliminary efficacy, and pharmacodynamics of CAL056 mesylate in cancer patients with resistant or…
- Trial name
- NCT04686383
- Testing
- CAL056 mesylate
- Where
- 3 sites in United States, Taiwan
- Volunteers
- 17 people
- Sponsor
- Calgent Biotechnology Co., Ltd
Cervical Cancer
Analysis of Parametrial Lymph Nodes as Sentinel Nodes in Patients With Cervical Cancer
The goal of this clinical research study is to find out if the parametrial nodes are "sentinel" nodes (the lymph nodes believed to be the greatest risk for the spread of cancer) and if intraoperative lymphatic mapping can…
- Trial name
- NCT00631241
- Testing
- Single Photon Emission Computed Tomography, Intraoperative Lymphatic Mapping
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
CD19 Positive, Philadelphia Chromosome Positive
Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia
This phase I/II studies the side effects of pembrolizumab and blinatumomab and to see how well they work in treating participants with acute lymphoblastic leukemia that has come back or has not responded to the treatment.
- Conditions
- CD19 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT03512405
- Testing
- Blinatumomab, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- City of Hope Medical Center
Non-small Cell Lung Cancer
Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
The purpose of this study is to understand if treatment with one chemotherapy medication combined with immune therapy (pembrolizumab) is tolerable and effective for patients with lung cancer and performance status of 2 (PS2)…
- Trial name
- NCT04297605
- Testing
- Pembrolizumab, Pemetrexed (Chemotherapy), Nab-paclitaxel (Chemotherapy)
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Rochester
High Grade Sarcoma, Sarcoma
Fluorescence-Guided Surgical Resection for Reducing Unexpected Positive Margins in Patients With Sarcoma, SarcoSIGHT Trial
This phase II trial compares standard of care surgical resection to fluorescence-guided surgical resection using indocyanine green and fluorescence imaging for reducing unexpected positive margin rates in patients with sarcoma.
- Trial name
- NCT07650656
- Testing
- Electronic Health Record Review, Fluorescence Imaging, Fluorescence-Guided Surgery
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- City of Hope Medical Center
Non-Small Cell Lung Cancer, Measles
Measles Vaccine in Patients With Measles Virus-Positive, Advanced Non-Small Cell Lung Cancer
The objectives of the study are to assess the efficacy and safety of live, attenuated measles vaccine as consolidation therapy in patients with measles-positive, non-small cell lung cancer with locally-advanced (stage 3B with…
- Trial name
- SMC4692 (NCT00828022)
- Testing
- attenuated measles vaccine
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Soroka University Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.